These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36379410)

  • 1. Efficacy of lanadelumab in angioedema due to acquired C1 inhibitor deficiency.
    Suffritti C; Sartorio S; Berra S; Janu VP; Caccia S; Zanichelli A
    J Allergy Clin Immunol Pract; 2023 Mar; 11(3):963-965.e1. PubMed ID: 36379410
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of lanadelumab in acquired angioedema with C1-inhibitor deficiency.
    Belbézier A; Boccon-Gibod I; Bouillet L
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2490-2491. PubMed ID: 33556593
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of lanadelumab in patients with hereditary angioedema with normal C1 inhibitor and FXII mutation.
    Bouillet L; Bocquet A; Belbezier A; Boccon-Gibod I
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):391-392. PubMed ID: 34082125
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema.
    Schlueter M; Nestler-Parr S
    J Comp Eff Res; 2024 May; 13(5):e230165. PubMed ID: 38545965
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful Use of Recombinant Human C1-INH in a Patient with Acquired Angioedema due to C1 Inhibitor Deficiency and an Unusually High Titer of Anti-C1-Inhibitor Autoantibodies.
    Jesenak M; Brndiarova M; Banovcin P; Varga L; Farkas H
    J Investig Allergol Clin Immunol; 2021 Jun; 31(3):255-256. PubMed ID: 32732186
    [No Abstract]   [Full Text] [Related]  

  • 6. Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit.
    Dorr AD; Chopra C; Coulter TI; Dempster J; Dziadzio M; El-Shanawany T; Garcez T; Gompels M; Herriot R; Jain R; Levi M; Lorenzo L; Makki I; Mapazire E; Murng SHK; Noorani S; Savic S; Steele CL; Symons C; Tarzi M; Yong PFK; Kiani-Alikhan S
    Allergy; 2023 May; 78(5):1369-1371. PubMed ID: 36510404
    [No Abstract]   [Full Text] [Related]  

  • 7. New drugs to treat hereditary angioedema.
    Scheinfeld N
    Skinmed; 2013; 11(6):357-9. PubMed ID: 24517042
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hereditary angioedema due to C1-esterase inhibitor deficiency : novel approaches].
    Stehlin F; Ribi C
    Rev Med Suisse; 2020 Apr; 16(689):675-678. PubMed ID: 32270933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three new drugs for hereditary angioedema.
    Med Lett Drugs Ther; 2010 Aug; 52(1345):66-7. PubMed ID: 20724964
    [No Abstract]   [Full Text] [Related]  

  • 10. Lanadelumab: First Global Approval.
    Syed YY
    Drugs; 2018 Oct; 78(15):1633-1637. PubMed ID: 30267321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical algorithm: Management of C1 inhibitor hereditary angioedema.
    Caballero T; Cabañas R; Pedrosa M
    Allergy; 2022 Mar; 77(3):1060-1063. PubMed ID: 34587298
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant human C1 esterase inhibitor as prophylactic treatment in idiopathic non-histaminergic angioedema.
    Alizadeh Aghdam M; Hofman ZLM; Meertens M; Lebens A; Hack CE; Knulst AC; Maas C; Röckmann H
    Allergy; 2022 Dec; 77(12):3673-3676. PubMed ID: 35837765
    [No Abstract]   [Full Text] [Related]  

  • 13. A case of normal C1 esterase inhibitor hereditary angioedema successfully treated with berotralstat.
    Kelbel T
    Ann Allergy Asthma Immunol; 2022 Apr; 128(4):462-463. PubMed ID: 35063629
    [No Abstract]   [Full Text] [Related]  

  • 14. Hereditary Angioedema.
    Busse PJ; Christiansen SC
    N Engl J Med; 2020 Mar; 382(12):1136-1148. PubMed ID: 32187470
    [No Abstract]   [Full Text] [Related]  

  • 15. Lanadelumab for the prevention of attacks in hereditary angioedema.
    Valerieva A; Senter R; Wu MA; Zanichelli A; Cicardi M
    Expert Rev Clin Immunol; 2019 Dec; 15(12):1239-1248. PubMed ID: 31721602
    [No Abstract]   [Full Text] [Related]  

  • 16. Recombinant human C1 esterase inhibitor as short-term prophylaxis in patients with hereditary angioedema.
    Valerieva A; Staevska M; Jesenak M; Hrubiskova K; Sobotkova M; Zachova R; Hakl R; Andrejevic S; Suiter T; Grivcheva-Panovska V; Karadza-Lapic L; Soteres D; Shapiro R; Rumbyrt J; Tachdjian R; Mehta V; Hsu FI; Zanichelli A
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):799-802. PubMed ID: 31437566
    [No Abstract]   [Full Text] [Related]  

  • 17. Benefits of hydroxychloroquine in the treatment of a patient with angioedema due to acquired C1 inhibitor deficiency.
    Vincent D; Ponard D; Fiorella S; Drouet C
    Ann Allergy Asthma Immunol; 2015 Jan; 114(1):68-70. PubMed ID: 25457864
    [No Abstract]   [Full Text] [Related]  

  • 18. A review of kallikrein inhibitor lanadelumab in hereditary angioedema.
    Hwang G; Johri A; Ng S; Craig T
    Immunotherapy; 2019 Aug; 11(11):937-944. PubMed ID: 31234673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study.
    Buttgereit T; Vera C; Weller K; Gutsche A; Grekowitz EM; Aykanat S; Wahn V; Krüger R; Maurer M; Magerl M
    J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3744-3751. PubMed ID: 34023564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lanadelumab (Takhzyro) for prevention of hereditary angioedema.
    Med Lett Drugs Ther; 2021 Mar; 63(1619):e41-e42. PubMed ID: 33755657
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.